Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
DHEA prevents and reverses chronic hypoxic pulmonary hypertension in a chronic
hypoxic-pulmonary hypertension model in the rat. However, no study has been performed in
human. The purpose of this study is to determine if DHEA is effective in the treatment of
respiratory pulmonary hypertension in adults with Chronic Obstructive Pulmonary Disease
(COPD) on exercise capacity and haemodynamic variables. Patients will receive after
randomisation either 25 mg/day or 200mg/day oral DHEA over a one-year period. Evaluation
concerns clinical parameters, echocardiography and right catheterization after and before
treatment. Primary end-point is the six-minute walk test. This is a prospective double blind,
randomised, placebo controlled study which will be realized in four university hospitals in
France : Bordeaux, Strasbourg, Toulouse and Limoges.